Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $9.99, but opened at $9.03. Curaleaf shares last traded at $9.70, with a volume of 7,706 shares traded.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Citigroup reiterated a “buy” rating on shares of Curaleaf in a report on Thursday, August 6th. Zacks Research upgraded Curaleaf from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Three investment analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. Based on data from MarketBeat, Curaleaf currently has a consensus rating of “Strong Buy”.
View Our Latest Stock Report on Curaleaf
Curaleaf Trading Down 1.3%
Curaleaf (OTCMKTS:CURLF – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.25. The company had revenue of $340.10 million for the quarter, compared to the consensus estimate of $332.00 million. Curaleaf had a negative net margin of 2.62% and a negative return on equity of 0.88%. As a group, analysts anticipate that Curaleaf Holdings, Inc. will post 0.01 EPS for the current fiscal year.
About Curaleaf
Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.
Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.
Recommended Stories
- Five stocks we like better than Curaleaf
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
- If Boeing Ramps Up Production, These Suppliers May Win Big
- Marvell Takes a Shot a Broadcom’s Throne With Google Deal
- 5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here’s Why
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
